chr2:197389784:> Detail (hg38)
Information
Genome
Assembly | Position |
---|---|
hg19 | chr2:198,254,508-198,299,803 |
hg38 | chr2:197,389,784-197,435,079 |
HGVS
Type | Transcript | Protein |
---|---|---|
Summary
MGeND
Clinical significance | |
Variant entry | |
GWAS entry | |
Disease area statistics | Show details |
Frequency
[No Data.]
Prediction
[No Data.]
ClinVar
Clinical Significance | |
Review star | [No Data.] |
Show details |
Links
Disease area statistics
[No Data.]
MGeND
[No Data.]
ClinVar
[No Data.]
CIViC
[No Data.]
DisGeNET
Score | Disease name | Description | Source | Pubmed | Links |
---|---|---|---|---|---|
0.008 | Congenital chromosomal disease | A 14-yr-old male was admitted to our hospital with MDS and the chromosomal abnor... | BeFree | 25130056 | Detail |
0.008 | Congenital chromosomal disease | The expression of unmutated immunoglobulin heavy chain variable region (IGHV) ge... | BeFree | 25563586 | Detail |
0.008 | Congenital chromosomal disease | Karyotype analysis was performed in 179 patients with AML or MDS with the differ... | BeFree | 26214902 | Detail |
<0.001 | colorectal carcinoma | NA | BeFree | Detail | |
<0.001 | Presenile dementia | NA | BeFree | Detail | |
<0.001 | dystonia | NA | BeFree | Detail | |
<0.001 | Eosinophilia | NA | BeFree | Detail | |
<0.001 | Focal glomerulosclerosis | NA | BeFree | Detail | |
<0.001 | Graft-vs-Host Disease | NA | BeFree | Detail | |
<0.001 | Heart Diseases | HIF-driven SF3B1 induces KHK-C to enforce fructolysis and heart disease. | BeFree | 26083752 | Detail |
0.001 | Hematological Disease | NA | BeFree | Detail | |
<0.001 | HIV Infections | NA | BeFree | Detail | |
<0.001 | Immune System Diseases | NA | BeFree | Detail | |
0.005 | leukemia | RUNX1 translocations and amplifications have been implicated in acute myeloblast... | BeFree | 24912843 | Detail |
0.127 | chronic lymphocytic leukemia | Through the European Research Initiative on chronic lymphocytic leukemia (CLL) (... | BeFree,CTD_human | 24943832 | Detail |
0.127 | chronic lymphocytic leukemia | We examined the significance of IgM peaks in chronic lymphocytic leukemia (CLL),... | BeFree,CTD_human | 24943833 | Detail |
0.127 | chronic lymphocytic leukemia | From pioneering studies, we know that certain genetic events are found in the ma... | BeFree,CTD_human | 25345442 | Detail |
0.127 | chronic lymphocytic leukemia | The impact of SF3B1 mutations in CLL on the DNA-damage response. | BeFree,CTD_human | 25371178 | Detail |
0.127 | chronic lymphocytic leukemia | Although TP53, NOTCH1, and SF3B1 mutations may impair prognosis of patients with... | BeFree,CTD_human | 26316624 | Detail |
<0.001 | Acute lymphocytic leukemia | NA | BeFree | Detail | |
0.040 | Leukemia, Myelocytic, Acute | A recent report in Nature now demonstrates that a specific mutation in mouse col... | BeFree | 24589711 | Detail |
0.040 | Leukemia, Myelocytic, Acute | In one patient (MDS/MPN-U) evolving to AML, the number of JAK2 mutant alleles de... | BeFree | 24845343 | Detail |
0.040 | Leukemia, Myelocytic, Acute | Although the frequency of evolution from hypocellular MDS to AML is low, our res... | BeFree | 25180186 | Detail |
0.040 | Leukemia, Myelocytic, Acute | Results confirm high frequencies of RAS and other activated signaling mutations ... | BeFree | 25331116 | Detail |
0.040 | Leukemia, Myelocytic, Acute | TP53 was the most common mutated gene in t-MDS (35.7%) as well as t-AML (33.3%),... | BeFree | 25573287 | Detail |
0.040 | Leukemia, Myelocytic, Acute | What came first: MDS or AML? | BeFree | 25721039 | Detail |
0.040 | Leukemia, Myelocytic, Acute | This TP53 mutation pattern was strikingly similar to that observed in de novo MD... | BeFree | 25952993 | Detail |
0.040 | Leukemia, Myelocytic, Acute | Karyotype analysis was performed in 179 patients with AML or MDS with the differ... | BeFree | 26214902 | Detail |
0.001 | myeloid leukemia | NA | BeFree | Detail | |
0.002 | Myeloid Leukemia, Chronic | NA | BeFree | Detail | |
0.008 | Leukemia, Myelomonocytic, Chronic | The study group included 13 MPN and four MDS/MPN patients (seven polycythemia ve... | BeFree | 24845343 | Detail |
0.001 | acute promyelocytic leukemia | NA | BeFree | Detail | |
0.001 | leukopenia | NA | BeFree | Detail | |
<0.001 | lymphedema | Heterozygous germline mutations in the zinc finger transcription factor GATA2 ha... | BeFree | 26214525 | Detail |
<0.001 | Lymphocytosis | By multivariate analysis, IgM peaks were associated with shorter treatment-free ... | BeFree | 24943833 | Detail |
0.002 | lymphoma | NA | BeFree | Detail | |
0.001 | melanoma | Rare SF3B1 R625 mutations in cutaneous melanoma. | BeFree | 24709888 | Detail |
0.004 | Monosomy | NA | BeFree | Detail | |
<0.001 | Movement Disorders | The Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDR... | BeFree | 25487881 | Detail |
0.001 | multiple myeloma | NA | BeFree | Detail | |
0.003 | Myelodysplasia | NA | BeFree | Detail | |
<0.001 | myelofibrosis | NA | BeFree | Detail | |
0.002 | Myeloproliferative disease | In one patient (MDS/MPN-U) evolving to AML, the number of JAK2 mutant alleles de... | BeFree | 24845343 | Detail |
<0.001 | Neoplasm Metastasis | NA | BeFree | Detail | |
<0.001 | polycythemia vera | The study group included 13 MPN and four MDS/MPN patients (seven polycythemia ve... | BeFree | 24845343 | Detail |
0.013 | Preleukemia | Disruption of SF3B1 results in deregulated expression and splicing of key genes ... | BeFree | 25428262 | Detail |
0.013 | Preleukemia | Splicing factor 3b subunit 1 (Sf3b1) haploinsufficient mice display features of ... | BeFree | 25481243 | Detail |
0.013 | Preleukemia | Guanine-adenine-thymine-adenine 2 (GATA2) mutated disorders include the recently... | BeFree | 25619630 | Detail |
0.013 | Preleukemia | By contrast, mutations affecting spliceosome genes SF3B1 and SRSF2, closely asso... | BeFree | 25732814 | Detail |
0.013 | Preleukemia | SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with rin... | BeFree | 25957392 | Detail |
0.013 | Preleukemia | Heterozygous germline mutations in the zinc finger transcription factor GATA2 ha... | BeFree | 26214525 | Detail |
<0.001 | Thrombocythemia, Essential | The study group included 13 MPN and four MDS/MPN patients (seven polycythemia ve... | BeFree | 24845343 | Detail |
<0.001 | Trisomy | NA | BeFree | Detail | |
<0.001 | Liver failure | NA | BeFree | Detail | |
0.003 | acute leukemia | NA | BeFree | Detail | |
<0.001 | Monocytosis | NA | BeFree | Detail | |
<0.001 | Cutaneous Melanoma | Rare SF3B1 R625 mutations in cutaneous melanoma. | BeFree | 24709888 | Detail |
<0.001 | hepatoblastoma | NA | BeFree | Detail | |
<0.001 | Adult Acute Myeloblastic Leukemia | NA | BeFree | Detail | |
0.122 | uveal melanoma | SF3B1 missense mutations were found in the two UMs with no BAP1 mutations. | BeFree,CTD_human | 25361747 | Detail |
0.122 | uveal melanoma | Using transcriptome sequencing data from chronic lymphocytic leukemia, breast ca... | BeFree,CTD_human | 25768983 | Detail |
<0.001 | secondary myelofibrosis | Among them, five patients (two PV, two MPN-U, and one MDS/MPN-U) progressed to M... | BeFree | 24845343 | Detail |
0.001 | Miller Dieker syndrome | NA | BeFree | Detail | |
<0.001 | Renal glomerular disease | NA | BeFree | Detail | |
<0.001 | Acquired aplastic anemia | NA | BeFree | Detail | |
<0.001 | Chronic lymphocytic leukaemia refractory | NA | BeFree | Detail | |
<0.001 | Cancer of Head and Neck | Regulation of HPV16 E6 and MCL1 by SF3B1 inhibitor in head and neck cancer cells... | BeFree | 25139387 | Detail |
<0.001 | Philadelphia chromosome positive chronic myelogenous leukemia | Few patients in remission of Ph-positive chronic myelogenous leukemia (CML) deve... | BeFree | 25631405 | Detail |
<0.001 | Refractory anemia with excess blasts in transformation (clinical) | NA | BeFree | Detail | |
<0.001 | Solid tumour | NA | BeFree | Detail | |
0.001 | secondary acute myeloid leukemia | NA | BeFree | Detail | |
<0.001 | de novo myelodysplastic syndromes | NA | BeFree | Detail | |
<0.001 | Iron Overload | Our studies suggest that SF3B1 mutations contribute to cellular iron overload in... | BeFree | 24854990 | Detail |
<0.001 | anaplastic astrocytoma | NA | BeFree | Detail | |
<0.001 | Richter's syndrome | NA | BeFree | Detail | |
0.001 | juvenile myelomonocytic leukemia | NA | BeFree | Detail | |
<0.001 | prediabetes syndrome | NA | BeFree | Detail | |
<0.001 | Malignant neoplasm of prostate | NA | BeFree | Detail | |
<0.001 | Hematopoietic Neoplasms | NA | BeFree | Detail | |
0.002 | Hematologic Neoplasms | Gene encoding splicing factors, especially splicing factor 3b subunit 1 (SF3B1),... | BeFree | 25651737 | Detail |
<0.001 | Dystonia Disorders | NA | BeFree | Detail | |
0.002 | Chromosome 8, trisomy | The aim of our study was 1) to define if the amplification of c-MYC, MLL and RUN... | BeFree | 26214902 | Detail |
<0.001 | dementia | NA | BeFree | Detail | |
<0.001 | Severe depression | NA | BeFree | Detail | |
<0.001 | Carcinogenesis | Significantly, we discovered that SF3B1 was involved in the splicing of oncogeni... | BeFree | 25139387 | Detail |
0.002 | Leukemogenesis | NA | BeFree | Detail | |
0.003 | Refractory anemias | Age, JAK2(V617F) and SF3B1 mutations are the main predicting factors for surviva... | BeFree | 23594705 | Detail |
<0.001 | Progressive Neoplastic Disease | Acquired defects in the p53 pathway, activating mutations of NOTCH1, and dysfunc... | BeFree | 25696844 | Detail |
0.001 | thrombocytosis | Age, JAK2(V617F) and SF3B1 mutations are the main predicting factors for surviva... | BeFree | 23594705 | Detail |
0.040 | Leukemia, Myelocytic, Acute | Among five patients diagnosed with MDS/MPN-U, three patients harboured RUNX1 (AM... | BeFree | 22571758 | Detail |
0.002 | breast carcinoma | SF3B1 mutations constitute a novel therapeutic target in breast cancer. | BeFree | 25424858 | Detail |
0.002 | breast carcinoma | The efficacy of the software is verified through MDS and clustering and tested w... | BeFree | 25905921 | Detail |
0.003 | Refractory anemia, without ringed sideroblasts, without excess blasts | Age, JAK2(V617F) and SF3B1 mutations are the main predicting factors for surviva... | BeFree | 23594705 | Detail |
0.002 | Myeloid Leukemia, Chronic | Previous studies have reported FLT3 mutation in as many as 9.2% of myeloprolifer... | BeFree | 23846442 | Detail |
0.001 | thrombocytosis | The remaining cases usually lack the JAK2(V617F)mutation, have a platelet count ... | BeFree | 21350094 | Detail |
0.001 | 5q-syndrome | NA | BeFree | Detail | |
<0.001 | Chromosome 12, 12p trisomy | NOTCH1 mutations correlated with a shorter treatment-free interval (p = 0.058), ... | BeFree | 24597984 | Detail |
0.001 | thrombocytosis | Sf3b1 (+/-) exhibited macrocytic anemia (MCV: 49.5 ± 1.6 vs 47.2 ± 1.4; Hgb: 5.5... | BeFree | 25481243 | Detail |
<0.001 | Leukemia secondary | NA | BeFree | Detail | |
<0.001 | myocardial hypoxia | Here we show that myocardial hypoxia actuates fructose metabolism in human and m... | BeFree | 26083752 | Detail |
<0.001 | Refractory anemia with ringed sideroblasts | NA | BeFree | Detail | |
0.001 | Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative | The study group included 13 MPN and four MDS/MPN patients (seven polycythemia ve... | BeFree | 24845343 | Detail |
0.001 | Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative | According to the 2008 WHO classification, the category of myelodysplastic/myelop... | BeFree | 25212680 | Detail |
0.002 | Chronic myeloproliferative disorder | In one patient (MDS/MPN-U) evolving to AML, the number of JAK2 mutant alleles de... | BeFree | 24845343 | Detail |
0.001 | Myelodysplastic Syndrome with Isolated del(5q) | NA | BeFree | Detail | |
0.001 | Therapy-related myelodysplastic syndrome | TP53 was the most common mutated gene in t-MDS (35.7%) as well as t-AML (33.3%),... | BeFree | 25573287 | Detail |
0.004 | Myelodysplastic-Myeloproliferative Diseases | Myeloproliferative neoplasms (MPN) and myelodysplastic/myeloproliferative neopla... | BeFree | 24845343 | Detail |
0.004 | Myelodysplastic-Myeloproliferative Diseases | According to the 2008 WHO classification, the category of myelodysplastic/myelop... | BeFree | 25212680 | Detail |
<0.001 | Eosinophilic disorder | NA | BeFree | Detail | |
<0.001 | Refractory anemia with excess blasts I | NA | BeFree | Detail | |
<0.001 | Refractory anemia with excess blasts II | NA | BeFree | Detail | |
<0.001 | Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome | NA | BeFree | Detail | |
0.001 | Treatment related acute myeloid leukaemia | NA | BeFree | Detail | |
<0.001 | colorectal cancer | NA | BeFree | Detail | |
<0.001 | Disorder characterized by eosinophilia | NA | BeFree | Detail | |
<0.001 | Milroy Disease | Guanine-adenine-thymine-adenine 2 (GATA2) mutated disorders include the recently... | BeFree | 25619630 | Detail |
0.001 | Chromosome 5, trisomy 5q | NA | BeFree | Detail | |
<0.001 | campomelic dysplasia | NA | BeFree | Detail | |
<0.001 | Precursor Cell Lymphoblastic Leukemia Lymphoma | NA | BeFree | Detail | |
<0.001 | Refractory anemia with ring sideroblasts associated with marked thrombocytosis | NA | BeFree | Detail | |
<0.001 | myeloid neoplasm | Guanine-adenine-thymine-adenine 2 (GATA2) mutated disorders include the recently... | BeFree | 25619630 | Detail |
0.003 | Refractory anemia, without ringed sideroblasts, without excess blasts | The splicing factor SF3B1 is the most commonly mutated gene in the myelodysplast... | BeFree | 25428262 | Detail |
<0.001 | Emberger syndrome | Guanine-adenine-thymine-adenine 2 (GATA2) mutated disorders include the recently... | BeFree | 25619630 | Detail |
0.011 | myelodysplastic syndrome | Disruption of SF3B1 results in deregulated expression and splicing of key genes ... | BeFree | 25428262 | Detail |
0.011 | myelodysplastic syndrome | Splicing factor 3b subunit 1 (Sf3b1) haploinsufficient mice display features of ... | BeFree | 25481243 | Detail |
0.011 | myelodysplastic syndrome | Guanine-adenine-thymine-adenine 2 (GATA2) mutated disorders include the recently... | BeFree | 25619630 | Detail |
0.011 | myelodysplastic syndrome | By contrast, mutations affecting spliceosome genes SF3B1 and SRSF2, closely asso... | BeFree | 25732814 | Detail |
0.011 | myelodysplastic syndrome | SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with rin... | BeFree | 25957392 | Detail |
0.011 | myelodysplastic syndrome | Heterozygous germline mutations in the zinc finger transcription factor GATA2 ha... | BeFree | 26214525 | Detail |
<0.001 | Progressive cGVHD | Acquired defects in the p53 pathway, activating mutations of NOTCH1, and dysfunc... | BeFree | 25696844 | Detail |
<0.001 | RETINOSCHISIS 1, X-LINKED, JUVENILE | NA | BeFree | Detail | |
0.001 | Primary myelofibrosis | NA | BeFree | Detail | |
0.002 | anemia | NA | BeFree | Detail | |
0.001 | aplastic anemia | NA | BeFree | Detail | |
<0.001 | Anemia, Macrocytic | Sf3b1 (+/-) exhibited macrocytic anemia (MCV: 49.5 ± 1.6 vs 47.2 ± 1.4; Hgb: 5.5... | BeFree | 25481243 | Detail |
0.003 | Refractory anemias | The splicing factor SF3B1 is the most commonly mutated gene in the myelodysplast... | BeFree | 25428262 | Detail |
0.004 | Refractory anaemia with excess blasts | NA | BeFree | Detail | |
<0.001 | Blast Phase | NA | BeFree | Detail | |
0.002 | Malignant neoplasm of breast | SF3B1 mutations constitute a novel therapeutic target in breast cancer. | BeFree | 25424858 | Detail |
0.002 | Malignant neoplasm of breast | The efficacy of the software is verified through MDS and clustering and tested w... | BeFree | 25905921 | Detail |
<0.001 | mucinous adenocarcinoma | Additional profiling of hotspot mutations in a panel of special histological sub... | BeFree | 25424858 | Detail |
Annotation
Annotations
Descrption | Source | Links |
---|---|---|
A 14-yr-old male was admitted to our hospital with MDS and the chromosomal abnormality 45,XY,der(5;1... | DisGeNET | Detail |
The expression of unmutated immunoglobulin heavy chain variable region (IGHV) genes, ZAP-70 and CD38... | DisGeNET | Detail |
Karyotype analysis was performed in 179 patients with AML or MDS with the different chromosomal aber... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
HIF-driven SF3B1 induces KHK-C to enforce fructolysis and heart disease. | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
RUNX1 translocations and amplifications have been implicated in acute myeloblastic leukemia, acute l... | DisGeNET | Detail |
Through the European Research Initiative on chronic lymphocytic leukemia (CLL) (ERIC), we screened 3... | DisGeNET | Detail |
We examined the significance of IgM peaks in chronic lymphocytic leukemia (CLL), including its assoc... | DisGeNET | Detail |
From pioneering studies, we know that certain genetic events are found in the majority of chronic ly... | DisGeNET | Detail |
The impact of SF3B1 mutations in CLL on the DNA-damage response. | DisGeNET | Detail |
Although TP53, NOTCH1, and SF3B1 mutations may impair prognosis of patients with chronic lymphocytic... | DisGeNET | Detail |
NA | DisGeNET | Detail |
A recent report in Nature now demonstrates that a specific mutation in mouse collagen-expressing ost... | DisGeNET | Detail |
In one patient (MDS/MPN-U) evolving to AML, the number of JAK2 mutant alleles decreased according to... | DisGeNET | Detail |
Although the frequency of evolution from hypocellular MDS to AML is low, our results suggest that so... | DisGeNET | Detail |
Results confirm high frequencies of RAS and other activated signaling mutations (10/12 AMLs) and ide... | DisGeNET | Detail |
TP53 was the most common mutated gene in t-MDS (35.7%) as well as t-AML (33.3%), significantly highe... | DisGeNET | Detail |
What came first: MDS or AML? | DisGeNET | Detail |
This TP53 mutation pattern was strikingly similar to that observed in de novo MDS/AML. | DisGeNET | Detail |
Karyotype analysis was performed in 179 patients with AML or MDS with the different chromosomal aber... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
The study group included 13 MPN and four MDS/MPN patients (seven polycythemia vera (PV); four essent... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Heterozygous germline mutations in the zinc finger transcription factor GATA2 have recently been sho... | DisGeNET | Detail |
By multivariate analysis, IgM peaks were associated with shorter treatment-free survival independent... | DisGeNET | Detail |
NA | DisGeNET | Detail |
Rare SF3B1 R625 mutations in cutaneous melanoma. | DisGeNET | Detail |
NA | DisGeNET | Detail |
The Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS), the Hoehn and Ya... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
In one patient (MDS/MPN-U) evolving to AML, the number of JAK2 mutant alleles decreased according to... | DisGeNET | Detail |
NA | DisGeNET | Detail |
The study group included 13 MPN and four MDS/MPN patients (seven polycythemia vera (PV); four essent... | DisGeNET | Detail |
Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myel... | DisGeNET | Detail |
Splicing factor 3b subunit 1 (Sf3b1) haploinsufficient mice display features of low risk Myelodyspla... | DisGeNET | Detail |
Guanine-adenine-thymine-adenine 2 (GATA2) mutated disorders include the recently described MonoMAC s... | DisGeNET | Detail |
By contrast, mutations affecting spliceosome genes SF3B1 and SRSF2, closely associated with the myel... | DisGeNET | Detail |
SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts. | DisGeNET | Detail |
Heterozygous germline mutations in the zinc finger transcription factor GATA2 have recently been sho... | DisGeNET | Detail |
The study group included 13 MPN and four MDS/MPN patients (seven polycythemia vera (PV); four essent... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Rare SF3B1 R625 mutations in cutaneous melanoma. | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
SF3B1 missense mutations were found in the two UMs with no BAP1 mutations. | DisGeNET | Detail |
Using transcriptome sequencing data from chronic lymphocytic leukemia, breast cancer and uveal melan... | DisGeNET | Detail |
Among them, five patients (two PV, two MPN-U, and one MDS/MPN-U) progressed to MF and three patients... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Regulation of HPV16 E6 and MCL1 by SF3B1 inhibitor in head and neck cancer cells. | DisGeNET | Detail |
Few patients in remission of Ph-positive chronic myelogenous leukemia (CML) develop Ph-negative MDS/... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Our studies suggest that SF3B1 mutations contribute to cellular iron overload in RARS/-T by deregula... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Gene encoding splicing factors, especially splicing factor 3b subunit 1 (SF3B1), have been shown to ... | DisGeNET | Detail |
NA | DisGeNET | Detail |
The aim of our study was 1) to define if the amplification of c-MYC, MLL and RUNX1 genes is related ... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Significantly, we discovered that SF3B1 was involved in the splicing of oncogenic HPV16 E6 to produc... | DisGeNET | Detail |
NA | DisGeNET | Detail |
Age, JAK2(V617F) and SF3B1 mutations are the main predicting factors for survival in refractory anae... | DisGeNET | Detail |
Acquired defects in the p53 pathway, activating mutations of NOTCH1, and dysfunctional mutations of ... | DisGeNET | Detail |
Age, JAK2(V617F) and SF3B1 mutations are the main predicting factors for survival in refractory anae... | DisGeNET | Detail |
Among five patients diagnosed with MDS/MPN-U, three patients harboured RUNX1 (AML1) mutations; one c... | DisGeNET | Detail |
SF3B1 mutations constitute a novel therapeutic target in breast cancer. | DisGeNET | Detail |
The efficacy of the software is verified through MDS and clustering and tested with available 11 fam... | DisGeNET | Detail |
Age, JAK2(V617F) and SF3B1 mutations are the main predicting factors for survival in refractory anae... | DisGeNET | Detail |
Previous studies have reported FLT3 mutation in as many as 9.2% of myeloproliferative neoplasms (MPN... | DisGeNET | Detail |
The remaining cases usually lack the JAK2(V617F)mutation, have a platelet count less than 600 × 10(3... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NOTCH1 mutations correlated with a shorter treatment-free interval (p = 0.058), an unmutated immunog... | DisGeNET | Detail |
Sf3b1 (+/-) exhibited macrocytic anemia (MCV: 49.5 ± 1.6 vs 47.2 ± 1.4; Hgb: 5.5 ± 1.7 vs 7.2 ± 1.0)... | DisGeNET | Detail |
NA | DisGeNET | Detail |
Here we show that myocardial hypoxia actuates fructose metabolism in human and mouse models of patho... | DisGeNET | Detail |
NA | DisGeNET | Detail |
The study group included 13 MPN and four MDS/MPN patients (seven polycythemia vera (PV); four essent... | DisGeNET | Detail |
According to the 2008 WHO classification, the category of myelodysplastic/myeloproliferative neoplas... | DisGeNET | Detail |
In one patient (MDS/MPN-U) evolving to AML, the number of JAK2 mutant alleles decreased according to... | DisGeNET | Detail |
NA | DisGeNET | Detail |
TP53 was the most common mutated gene in t-MDS (35.7%) as well as t-AML (33.3%), significantly highe... | DisGeNET | Detail |
Myeloproliferative neoplasms (MPN) and myelodysplastic/myeloproliferative neoplasms (MDS/MPN) may tr... | DisGeNET | Detail |
According to the 2008 WHO classification, the category of myelodysplastic/myeloproliferative neoplas... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Guanine-adenine-thymine-adenine 2 (GATA2) mutated disorders include the recently described MonoMAC s... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Guanine-adenine-thymine-adenine 2 (GATA2) mutated disorders include the recently described MonoMAC s... | DisGeNET | Detail |
The splicing factor SF3B1 is the most commonly mutated gene in the myelodysplastic syndrome (MDS), p... | DisGeNET | Detail |
Guanine-adenine-thymine-adenine 2 (GATA2) mutated disorders include the recently described MonoMAC s... | DisGeNET | Detail |
Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myel... | DisGeNET | Detail |
Splicing factor 3b subunit 1 (Sf3b1) haploinsufficient mice display features of low risk Myelodyspla... | DisGeNET | Detail |
Guanine-adenine-thymine-adenine 2 (GATA2) mutated disorders include the recently described MonoMAC s... | DisGeNET | Detail |
By contrast, mutations affecting spliceosome genes SF3B1 and SRSF2, closely associated with the myel... | DisGeNET | Detail |
SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts. | DisGeNET | Detail |
Heterozygous germline mutations in the zinc finger transcription factor GATA2 have recently been sho... | DisGeNET | Detail |
Acquired defects in the p53 pathway, activating mutations of NOTCH1, and dysfunctional mutations of ... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Sf3b1 (+/-) exhibited macrocytic anemia (MCV: 49.5 ± 1.6 vs 47.2 ± 1.4; Hgb: 5.5 ± 1.7 vs 7.2 ± 1.0)... | DisGeNET | Detail |
The splicing factor SF3B1 is the most commonly mutated gene in the myelodysplastic syndrome (MDS), p... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
SF3B1 mutations constitute a novel therapeutic target in breast cancer. | DisGeNET | Detail |
The efficacy of the software is verified through MDS and clustering and tested with available 11 fam... | DisGeNET | Detail |
Additional profiling of hotspot mutations in a panel of special histological subtypes of breast canc... | DisGeNET | Detail |
Overlapped Transcript Coordinates
Gene | Transcript ID | Exon Number | Chromosome | Start | Stop | Type | Amino Mutation | Transcript Position | Links |
---|
Overlapped Transcript
Gene | Transcript ID | Chromosome | Start | Stop | Links |
---|
- Gene
- -
- dbSNP
- rs386626619 dbSNP
- Genome
- hg38
- Position
- chr2:197,389,784-197,435,079
- Variant Type
- snv
Genome browser